Scorpius announced a partnership with Celltheon Corporation to provide cell line development services to clients using Celltheon’s proprietary GOLDILOCKS transposase-based platform. This collaboration enables clients to integrate with Scorpius’ program management team and quality system while preparing to transfer a research cell bank to the Company’s facilities in San Antonio, TX, for further biomanufacturing work. In addition to full-scale cell line development services, Celltheon offers Scorpius clients services in antibody discovery, variant screening and development, and comparability studies. The first client signed under this partnership aims to scale up to GMP manufacturing with Scorpius.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SCPX:
- Scorpius Holdings announces implementation of new cost saving measures
- Scorpius Holdings announces partnership with U.S. biotech company
- Scorpius Holdings selected to join Medical CBRN Defense Consortium
- Scorpius signs contract to provide bioanalytical services to biotech company
- Scorpius Holdings initiated with a Buy at ThinkEquity
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
